Alzheimers Disease Diagnosis

1
Alzheimers Disease Diagnosis
Invention Multiplexed Biomarkers for Alzheimers
Disease Diagnosis
Inventors
Dr. Kelvin Lee
Professor of Molecular and Cell Biology Director,
Cornell Institute for Biotechnology and Life
Sciences Technologies
Dr. Norman Relkin
Assoc. Professor of Clinical Neurology and
Neuroscience
2
Alzheimers Disease Diagnosis
Market Opportunity

• By 2005, 24 million people worldwide have
  been diagnosed with Alzheimer's Disease.
• 2040 Projection 80 million.

• Current diagnosis is based on patient history and
  exclusion of other neurological disorders.

• Most patients are not diagnosed until neuronal
  damage are severe.

• Diagnostic markers would allow earlier diagnosis
  and treatment.

3
Alzheimers Disease Diagnosis
Cornell Technology

• CSF biomarkers for AD were identified using
  proteomic method.

• A panel of 23 proteins are used for diagnosis

• Statistic method based on multiple variables is
  more specific and accurate than single markers.

A Sensitivity of 94, specificity of 94, and
predicted classification error rate of 5.9 is
achieved.
4
Alzheimers Disease Diagnosis
Developmental status

• Cornell AD marker panel was used to evaluate
  patients in a phase I clinical trial for a drug
  to treat AD, together with traditional clinical
  diagnostic method for AD.

• Results from Cornell AD marker panel are
  consistent with those of the clinical diagnosis.

• Analysis for the samples from the phase II
  clinical trial is ongoing.

• Cornell AD maker panel is the first clinical
  validated diagnostic system for AD other than the
  traditional methods based on patient history,
  brain imaging, and neuropsychological testing.

5
Alzheimers Disease Diagnosis
Technology Availability
IP PCT/US2006/013234 was filed.
Licensing exclusive and non-exclusive rights
currently available.
Contact Alice Li xl11_at_cornell.edu
www.cctec.cornell.edu